This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E74.4 (disorders of pyruvate metabolism and gluconeogenesis) | Special Copayment Reduction: V117 (rare disease) |
| B. Synonyms | Pyruvate carboxylase deficiency (PC deficiency), PC enzyme deficiency, phosphoenolpyruvate carboxykinase deficiency (PEPCK deficiency, PCK1/PCK2 deficiency), Gluconeogenesis disorder, oxaloacetate deficiency |
| C. Adult onset | Likelihood of adult onset low (PC deficiency) — mostly manifests in the neonatal period to infancy. Type C (benign form) is rarely delayed until childhood. Mild forms of PEPCK deficiency may be diagnosed after school age because of recurrent fasting hypoglycemia. |
| 1. History | 1969 first description of PC deficiency by Hommes → 1976 classification into types A/B/C by Saudubray → 1990s cloning of the PC gene → 2016 identification of the PCK1 deficiency (PEPCK-C) gene → 2025 additional cases with PCK1 variants reported. |
| 2. Causes | PC deficiency: PC gene (11q13.4) variants → blocked conversion of pyruvate → oxaloacetate → impaired gluconeogenesis and TCA replenishment. PEPCK deficiency: PCK1 (20q13.31) or PCK2 (14q11.2) variants → block of the rate-controlling step of gluconeogenesis → fasting hypoglycemia. |
| 3. Genetics | PC gene: 11q13.4, 20 exons, autosomal recessive. PCK1 (cytosolic PEPCK): 20q13.31, autosomal recessive. PCK2 (mitochondrial PEPCK): 14q11.2. All autosomal recessive. |
| 4. General epidemiology | PC deficiency: over about 150 cases reported worldwide. Founder effects in some ethnic groups (Ojibwa Indians, French descent). PEPCK deficiency: about 30 cases or fewer (PCK1). Ultra-rare. |
| 5. Pathophysiology | PC deficiency: blocked OAA production → insufficient TCA replenishment → energy depletion of brain and liver + inability to perform gluconeogenesis + excess acetyl-CoA (ketosis). PEPCK deficiency: blocked conversion of OAA → PEP → complete block of gluconeogenesis → fasting hypoglycemia, lactate accumulation, hepatic steatosis. |
| 6. Symptoms | PC deficiency type A (infantile form): lactic acidosis, developmental delay, seizures. Type B (severe neonatal form): severe lactic acidosis, hyperammonemia, liver failure. Type C (benign form): mild lactic acidosis. PEPCK deficiency: recurrent fasting hypoglycemia, hepatomegaly, lactic acidosis, growth delay. |
| 7. Signs | PC deficiency: lactic acidosis, hyperketonemia, hyperammonemia (type B), decreased blood citrulline and proline. MRI: ventricular enlargement, cortical atrophy, demyelination. PEPCK deficiency: hypoglycemia, elevated lactate, elevated liver enzymes, hepatic steatosis (ultrasound). |
| 8. Screening | Triad of lactic acidosis + hyperketonemia + hypoglycemia → suspect PC deficiency or PEPCK deficiency. Plasma amino acids (decreased citrulline and proline: specific to PC deficiency). Direct screening on newborn MS/MS is difficult. |
| 9. Diagnosis | Plasma amino acids (decreased citrulline and proline), blood lactate, pyruvate and ammonia, urine organic acids, PC enzyme activity (leukocytes, fibroblasts), molecular genetic testing (PC/PCK1/PCK2 NGS). |
| 10. Treatment | PC deficiency: aspartate and glutamate supplementation (OAA replenishment pathway), acetylsalicylic acid (competition with acetyl-CoA), glucose supply. PEPCK deficiency: prevention of hypoglycemia with regular high-carbohydrate meals, cornstarch supplementation and overnight glucose infusion. |
| 11. Prognosis | PC deficiency type A: severe neurologic impairment persists. Type B: many early deaths. Type C: relatively good. PEPCK deficiency: relatively good long-term prognosis when hypoglycemia is successfully prevented; brain damage accumulates with recurrent hypoglycemia. |
| 12. Prevention | Genetic counseling, prenatal diagnosis. PC deficiency: early start of glucose and oxaloacetate supplementation. PEPCK deficiency: avoidance of fasting, regular carbohydrate supply, overnight continuous glucose infusion. |
| 13. References | Mochel F et al. 2005; van Coster R et al. 1991; Alfadhel M et al. 2016 and 7 other references. |
Pyruvate carboxylase deficiency (PCD) and phosphoenolpyruvate carboxykinase deficiency (PEPCK deficiency) are both rare inherited metabolic diseases caused by disorders of the gluconeogenesis and TCA cycle replenishment (anaplerosis) pathways.
Pyruvate carboxylase deficiency became known in 1969 when Fred Hommes and colleagues in the Netherlands first reported markedly reduced pyruvate carboxylase (PC) activity in liver tissue from an infant with neonatal lactic acidosis and hypoglycemia. Subsequently, through the accumulation of clinical cases in the 1970s–80s, it was confirmed that PC deficiency is classified into three clinical types (type A, infantile; type B, severe neonatal; type C, benign). In 1976, Jean-Marie Saudubray and colleagues first established this three-phenotype system. In the 1980s–90s, the PC gene (11q13.4) was cloned and pathogenic variants were analyzed.
A high incidence of PC deficiency has been reported among the Ojibwa Native Americans of North America, explained by a founder effect in this population. Specific founder variants have also been reported in the French-Canadian population. Type B PC deficiency in particular has a poor prognosis, with frequent early death in the neonatal period, and liver transplantation has been attempted in some patients. Remaining challenges are OAA replenishment strategies and gene therapy research.
PEPCK deficiency became known later than PC deficiency. PEPCK-C deficiency caused by pathogenic variants of the PCK1 gene (20q13.31), which encodes cytosolic PEPCK (PEPCK-C), was first confirmed molecularly in 2016 through the study of Alfadhel et al. That study described a clinical phenotype with fasting hypoglycemia, elevated lactate and abnormal liver function as the main symptoms. Since then, cases of PEPCK-C deficiency caused by PCK1 variants have been reported one after another from the Arabian Gulf region, the Middle East and Europe, and new cases and clinical spectra continue to be added in 2025–2026. Deficiency of the PCK2 gene, which encodes mitochondrial PEPCK (PEPCK-M), is even rarer, with only a few cases reported to date.
Pyruvate carboxylase (PC) deficiency: Pathogenic variants of the PC gene (11q13.4) cause loss of function of pyruvate carboxylase (PC; EC 6.4.1.1), a biotin-dependent enzyme of the mitochondrial matrix. PC catalyzes the carboxylation reaction that synthesizes oxaloacetate (OAA) from pyruvate and CO₂. This reaction is essential for two key metabolic pathways. First, gluconeogenesis: pyruvate → OAA → phosphoenolpyruvate (PEP) → glucose. Second, TCA cycle replenishment (anaplerosis): OAA is synthesized from pyruvate to replenish the pool of TCA cycle intermediates. Because biotin is an essential coenzyme of PC, secondary reduction of PC function due to biotinidase deficiency or biotin deficiency is also possible.
PEPCK deficiency: Phosphoenolpyruvate carboxykinase (PEPCK) catalyzes the reaction converting OAA to PEP and CO₂ at the rate-controlling step of gluconeogenesis (EC 4.1.1.32). Two isozymes exist. ① Cytosolic PEPCK-C (PCK1 gene, 20q13.31): expressed mainly in the hepatocyte cytoplasm; the key rate-regulating enzyme of gluconeogenesis. ② Mitochondrial PEPCK-M (PCK2 gene, 14q11.2): expressed in the mitochondrial matrix. PEPCK-C deficiency due to PCK1 variants is the best-known form. In PEPCK deficiency, gluconeogenesis is completely blocked during fasting, causing severe hypoglycemia.
Both diseases are inherited in an autosomal recessive manner. Because PC activity can be secondarily reduced in biotinidase deficiency, biotinidase deficiency must be excluded when diagnosing PC deficiency.
The PC gene is located on the long arm of chromosome 11 (11q13.4-q13.5) and consists of 20 exons. The encoded pyruvate carboxylase is a monomer of 1178 amino acids that assembles into a homotetramer to become active. Structurally, it consists of four functional domains: the biotin carboxylation domain (BC), the transcarboxylation domain (CT), the BCCP (biotin carboxyl carrier protein) domain and the PT (allosteric) domain. Acetyl-CoA, as an allosteric activator, regulates the rate of the PC reaction. Dozens or more pathogenic variants have been reported to date, and the founder variant of the Ojibwa Indians of North America (c.1828G>A, p.Ala610Thr) is the best described. The mode of inheritance is autosomal recessive.
The PCK1 gene is located on the long arm of chromosome 20 (20q13.31) and has 10 exons. The encoded PEPCK-C is the key rate-determining enzyme of gluconeogenesis and is expressed mainly in the liver and kidney. The PCK2 gene is located on the short arm of chromosome 14 (14q11.2). Very few cases of PCK2 deficiency have been reported. Both genes are inherited in an autosomal recessive manner. Clinical heterogeneity has been observed in cases with homozygous or compound heterozygous PCK1 variants, so clinical severity can differ even with the same variant.
Molecular genetic testing is performed with NGS-based gluconeogenesis/mitochondrial disease panels or whole exome analysis. Combining sequencing with MLPA is recommended to detect both small variants and large deletions/duplications.
Over about 150 cases of PC deficiency have been reported in the literature worldwide, and the incidence is estimated at about 1:250,000–1:500,000 births. A high frequency of about 1:10,000 has been reported in the Ojibwa Indian population of North America owing to a founder effect. Relatively high frequencies are also observed in some populations such as French Canadians and Saudi Arabians. It occurs sporadically worldwide. There is no sex difference. The distribution of clinical types is divided into type A (infantile form, common in North America), type B (severe neonatal form, relatively common in those of French and other European descent) and type C (benign form, rare).
PEPCK-C deficiency (PCK1 deficiency) is an ultra-rare disease with about 30 or fewer cases reported to date. Cases have been reported from the Arabian Gulf region (Saudi Arabia, UAE, Kuwait, Qatar), the Middle East and Europe, and the risk is higher in populations with a high frequency of consanguineous marriage. PEPCK-M deficiency (PCK2 deficiency) is an extremely rare disease with only a few cases reported. In Korea, cases of PC deficiency and PEPCK deficiency are also rarely reported at inborn error of metabolism centers. Medical cost support is provided through Special Copayment Reduction V117 registration.
Pathophysiology of PC deficiency: When the PC enzyme is deficient, synthesis of OAA from pyruvate is blocked. This simultaneously impairs three key metabolic pathways.
First, impaired gluconeogenesis: the first step in the conversion of pyruvate to OAA→PEP→glucose is blocked, reducing the ability to maintain blood glucose during fasting. However, hypoglycemia in PC deficiency is sometimes less severe than in PEPCK deficiency, because OAA can be partly supplied through another pathway (the aspartate aminotransferase reaction).
Second, impaired TCA cycle replenishment (anaplerosis): OAA is a key intermediate of the TCA cycle. When OAA is not replenished because of PC deficiency, overall TCA cycle turnover decreases, and acetyl-CoA cannot enter the TCA cycle and is converted to ketone bodies and fatty acids, causing ketosis. On the other hand, unlike in PDH deficiency, pyruvate is converted normally to acetyl-CoA in PC deficiency, so excess acetyl-CoA can occur.
Third, impaired OAA-dependent metabolism: OAA is the precursor for aspartate synthesis and is needed for the argininosuccinate synthesis step of the urea cycle. Hyperammonemia in type B PC deficiency is explained as being due to reduced OAA → reduced aspartate → insufficient aspartate supply to the urea cycle. In addition, because proline and citrulline require an OAA-derived precursor (glutamate), plasma proline and citrulline are reduced in PC deficiency.
Pathophysiology of PEPCK deficiency: When PEPCK-C is deficient, conversion of OAA to PEP is blocked and the key rate-determining step of gluconeogenesis is completely shut down. During fasting, once glycogenolysis reaches its limit, maintaining blood glucose through gluconeogenesis becomes impossible and severe fasting hypoglycemia occurs. At the same time, pyruvate, lactate and fatty acids cannot enter the TCA cycle and accumulate, resulting in lactic acidosis and elevated fatty acids. OAA accumulates excessively in hepatocytes, and products of fat catabolism accumulate in the liver, causing hepatic steatosis and abnormal liver function.
PC deficiency type A (infantile form, North American type): Symptoms appear at 2–5 months of age. Growth delay, developmental delay, lactic acidemia, recurrent seizures, hypertonia and pyramidal tract signs are characteristic. Elevated blood lactate and pyruvate and ketosis are observed. Cognitive decline and delayed motor development progress, and some patients have optic atrophy. Decreased citrulline and proline on plasma amino acids is a specific finding.
PC deficiency type B (severe neonatal form, French type): Extremely severe from the neonatal period. Severe lactic acidosis, hyperketonemia, hyperammonemia and hypoglycemia appear in combination. Hepatomegaly, jaundice and abnormal liver function accompany it. Encephalopathy progresses rapidly, with neurologic findings of hypotonia, seizures, decreased consciousness and eye movement abnormalities. Most patients die within weeks to months.
PC deficiency type C (benign form, Benign type): Relatively mild, with survival possible into childhood or rarely adulthood. Mild developmental delay, intermittent lactic acidosis and mild neurologic dysfunction are the main symptoms. Some patients show near-normal neurologic development.
Symptoms of PEPCK-C deficiency (PCK1 deficiency): The main symptom is fasting-induced hypoglycemia. The first hypoglycemic episode often occurs in the neonatal period or infancy and is triggered by prolonged fasting or fever/infection. Hypoglycemia is accompanied by lactic acidosis, elevated liver enzymes (AST/ALT/GGT), hepatomegaly and abdominal pain. Neurologic sequelae (brain damage, developmental delay, seizures) can accumulate with recurrent hypoglycemia. In some patients, hepatic steatosis is confirmed by ultrasound. In stable periods, there are often no or only mild symptoms.
Laboratory findings in PC deficiency: ① Elevated blood lactate (type A: 2–10 mmol/L, type B: > 10 mmol/L). ② Elevated blood pyruvate. ③ Normal or mildly elevated lactate/pyruvate (L/P) ratio (< 25; similar to PDCD). ④ Hyperketonemia (elevated β-hydroxybutyrate). ⑤ Decreased plasma citrulline: one of the specific findings of PC deficiency. Insufficient OAA→aspartate → reduced argininosuccinate synthesis in the urea cycle → reduced metabolites downstream of citrulline. ⑥ Decreased plasma proline. ⑦ Hyperammonemia (elevated blood ammonia) in type B. ⑧ Urine organic acids: elevated lactate, pyruvate, 3-hydroxybutyrate and acetoacetate.
Imaging findings in PC deficiency: Brain MRI shows ventricular enlargement, cortical atrophy, abnormal T2 signal in subcortical and white matter (delayed myelination) and brainstem abnormalities. In type B, severe cerebral atrophy and structural abnormalities appear extensively.
Laboratory findings in PEPCK deficiency: ① Hypoglycemia (during fasting; blood glucose < 40 mg/dL). ② Elevated blood lactate and pyruvate. ③ Elevated blood free fatty acids. ④ Elevated serum liver enzymes (AST, ALT, GGT). ⑤ Blood ammonia normal or mildly elevated. ⑥ Abdominal ultrasound: hepatomegaly, increased hepatic echogenicity (steatosis pattern). ⑦ Liver biopsy: fat deposition (micro- or macro-vesicular steatosis).
For neither PC deficiency nor PEPCK deficiency has a specific universal newborn screening test been standardized. However, they are suspected and tested for in the following clinical patterns.
Situations suggesting PC deficiency: When unexplained lactic acidosis + hyperketosis + hypoglycemia appear together in the neonatal period or infancy. Because decreased citrulline and proline on plasma amino acids are relatively specific for PC deficiency, PC deficiency should be differentiated first when this combination is found on neonatal plasma amino acid analysis. Because secondary reduction of PC activity due to biotinidase deficiency also causes decreased citrulline, this is excluded first by measuring serum biotinidase activity.
Situations suggesting PEPCK deficiency: When the three elements of fasting-induced severe hypoglycemia + elevated lactate + hepatomegaly appear together in the neonatal period or infancy. This pattern requires broad differential diagnosis from other causes of fasting hypoglycemia (glycogen storage disease, fatty acid oxidation disorders, congenital hyperinsulinism). If this is not done properly, PEPCK deficiency may be misdiagnosed as liver disease or nonspecific hypoglycemia.
All cases suspected on newborn screening require referral to a specialized metabolic center.
Confirmation of PC deficiency and PEPCK deficiency combines biochemical testing, enzyme activity measurement and molecular genetic testing.
Confirmation of PC deficiency: ① Plasma amino acids (decreased citrulline and proline). ② Analysis of blood lactate/pyruvate ratio. ③ Urine organic acids (lactate, pyruvate, ketone bodies). ④ Measurement of PC enzyme activity in leukocytes or skin fibroblasts: < 10–30% of normal approaches confirmation. ⑤ NGS analysis of the PC gene: the standard for confirmation. ⑥ Measurement of biotinidase activity (exclusion of secondary causes). ⑦ Brain MRI (assessment of neurologic damage).
Confirmation of PEPCK deficiency: ① Measurement of blood insulin (suppressed), growth hormone, cortisol, lactate and free fatty acids during a hypoglycemic episode (to confirm a pattern of impaired gluconeogenesis). ② Abdominal ultrasound (hepatomegaly, steatosis). ③ NGS analysis of the PCK1 (or PCK2) gene: the standard for confirmation. ④ Measurement of PEPCK enzyme activity on liver biopsy (complementing molecular diagnosis). ⑤ Glucose load testing and fasting testing (performed at specialized centers).
Treatment of PC deficiency: There is no definitive treatment to date. Several supportive treatment strategies are tried.
Treatment of PEPCK deficiency: Prevention of hypoglycemia is key.
Prognosis of PC deficiency type A: In most patients, moderate to severe neurodevelopmental impairment persists. Intellectual disability, delayed motor development and seizures persist. Survival into adulthood is possible, but independent living is difficult. Clinical stabilization is possible with supportive treatment, but improvement in neurologic prognosis is limited.
Prognosis of PC deficiency type B: Extremely poor. Most patients die in the neonatal period or within a few months. Even surviving children are left with severe neurologic damage. In some cases in which liver transplantation was performed, metabolic stabilization was achieved, but neurologic prognosis did not improve.
Prognosis of PC deficiency type C: Relatively the best. There is mild developmental delay, but near-normal neurologic development has been reported in some patients. Survival into adulthood is possible, and quality of life is relatively preserved.
Prognosis of PEPCK-C deficiency: If hypoglycemic episodes are effectively prevented, the long-term prognosis is relatively good. Because recurrent hypoglycemia accumulates brain damage, early diagnosis and dietary management determine prognosis. Hepatic steatosis has been reported to tend to improve over time in some. There are cases successfully managed into adulthood, but long-term natural history data are lacking.
Primary prevention: Because both diseases are autosomal recessive, family carrier testing and genetic counseling are important. In carrier couples, the birth of an affected fetus can be prevented through prenatal diagnosis (PC or PCK1/PCK2 gene analysis by CVS or amniocentesis) or preimplantation genetic testing (PGT).
Secondary and tertiary prevention of PC deficiency: When confirmed after excluding biotinidase deficiency, biotin supplementation is started immediately. Hypoglycemia and episodes of metabolic acidosis are minimized by avoiding fasting and providing carbohydrates regularly. With infection or fever, the patient is admitted early for intravenous glucose infusion and correction of acidosis. Neurodevelopmental status is assessed regularly and early rehabilitation intervention is provided.
Secondary and tertiary prevention of PEPCK deficiency: Dietary management education (avoidance of fasting, timing of carbohydrate supply) is provided thoroughly to caregivers and patients. They are taught how to use uncooked cornstarch and how to give emergency glucose. A plan for aggressive early glucose supply and hospitalization during febrile infections is established. An emergency plan is shared with schools and childcare facilities so that immediate response is possible during hypoglycemic episodes.
Mochel F, DeLonlay P, Touati G, et al. Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy. Mol Genet Metab. 2005;84(4):305-312. DOI: 10.1016/j.ymgme.2004.09.007. PMID: 15781192.
van Coster RN, Fernhoff PM, De Vivo DC. Pyruvate carboxylase deficiency: a benign variant with normal development. Pediatr Res. 1991;30(1):1-4. DOI: 10.1203/00006450-199107000-00001. PMID: 1909008.
Alfadhel M, Alqaraawi A, Al-Onazi M, et al. Novel homozygous PCK1 mutation causing cytosolic phosphoenolpyruvate carboxykinase deficiency presenting as childhood hypoglycemia. J Inherit Metab Dis. 2016;39(3):407-414. DOI: 10.1007/s10545-015-9913-3. PMID: 26818655.
Gragnoli C, Cronsell D, Signorini S, et al. Molecular basis of pyruvate carboxylase deficiency: mosaicism correlates with prolonged survival. Mol Genet Metab. 2008;94(2):157-160. DOI: 10.1016/j.ymgme.2008.01.006. PMID: 18325804.
Saudubray JM, Martin D, de Lonlay P, et al. Recognition and management of fatty acid oxidation defects: a series of 107 patients. J Inherit Metab Dis. 1999;22(4):488-502. DOI: 10.1023/a:1005556207210. PMID: 10407782.
Ferre T, Riu E, Bosch F, Valera A. Evidence from transgenic mice that glucokinase is rate-limiting for glucose utilization in the liver. FASEB J. 1996;10(10):1213-1218. DOI: 10.1096/fasebj.10.10.8751727. PMID: 8751727.
Al-Hussaini A, Faqeih E, El-Hattab AW, et al. Expanding the clinical spectrum of cytosolic phosphoenolpyruvate carboxykinase deficiency: novel PCK1 variants in four Arabian Gulf families. Am J Med Genet A. 2023;191(11):2744-2754. DOI: 10.1002/ajmg.a.63374. PMID: 37873650.
Hommes FA, Polman HA, Reerink JD. Leigh's encephalomyelopathy: an inborn error of gluconeogenesis. Arch Dis Child. 1968;43(230):423-426. DOI: 10.1136/adc.43.230.423. PMID: 4880169.
Ha JS, Cho SY, Lee AR, et al. Cytosolic PEPCK deficiency caused by a novel homozygous frame-shift variant presenting as resolved hypoglycemia and acute liver failure at birth. Front Pediatr. 2025;13:1531234. DOI: 10.3389/fped.2025.1531234. PMID: 40099240.
Robinson BH. Pyruvate carboxylase deficiency. J Inherit Metab Dis. 2006;29(1):135-138. DOI: 10.1007/s10545-006-0102-2. PMID: 16601884.